Could label update for diabetes med Jardiance boost drug class?

A new forecast predicts the so-called SGLT-2 diabetes drugs, headlined by Jardiance, could become the third best-selling class of drugs by 2022. 

By Nicole Gray • June 22, 2016

Austin biotech Savara adds two lung drugs in deal for Serendex

Savara raised $20 million in March to advance its lead drug, an inhaled antibiotic, into Phase 3 testing. 

By Nicole Gray • June 22, 2016

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

Philips ad for lung device wins top honors at Cannes

Several big pharma companies, such as Pfizer and Teva, also took awards for their ads at the international marketing competition. 

By Nicole Gray • June 21, 2016

Clinton racks up donations from pharma industry

Although individual donations from pharma made up a small share of Clinton's overall fundraising, her total far exceeded amounts raised by Donald Trump or Bernie Sanders. 

By Nicole Gray • June 20, 2016

NIH turns down request to override cancer drug patent

Consumer groups had argued the $129,000 price tag for Xtandi limits patient access, justifying intervention by the government under a little-used law.

By Ned Pagliarulo • June 20, 2016

Doubling down on biosimilars, Novartis plans five launches by 2020

The Swiss giant aims to introduce biosimilar copies of blockbuster biologic drugs, such as AbbVie's Humira and Roche's Rituxan, by the end of the decade. 

By Ned Pagliarulo • June 20, 2016

Why Novartis' new heart med could reverse slow start

BioPharma Dive spoke to Clyde Yancy, Chief of Cardiology at Northwestern University, about the new clinical practice guidelines recommending Entresto.

By Nicole Gray • June 17, 2016

Payer interest grows in outcomes-based drug deals: report

Health plans were particularly interested in pay-for-performance deals for hepatitis C and oncology therapies, according to a survey conducted by Avalere 

By Nicole Gray • June 17, 2016

Roche's combo melanoma treatment turned down by UK cost watchdog

While the combination of Cotellic and Zelboraf is approved in Europe, the U.K. agency deemed the drugs not cost-effective. 

By Nicole Gray • June 17, 2016

Lilly and Boehringer's Jardiance sets new bar, shows kidney benefit

Other drugmakers have rushed to match the drug's previously proven cardiovascular benefit, but new data shows it can help slow the progression of kidney disease. 

By Nicole Gray • June 15, 2016

Success rate for clinical trials climbed in recent years: study

Research published in Nature showed an 11.6% likelihood of drugs moving from Phase 1 to launch, higher than another study recently conducted by BIO. 

By Nicole Gray • June 15, 2016

FDA wants to suspend more than 4,000 illegal Rx sites

U.S. consumers have purchased unapproved medications from international sellers to treat depression, narcolepsy, glaucoma and other medical conditions. 

By Nicole Gray • June 10, 2016

Alexandria Center for Life Sciences offers $25M in seed funding for small biotechs

Alexandria LaunchLabs is accepting applications for biotech start-ups looking for seed funding and space in New York. 

By Nicole Gray • June 9, 2016

Will the approval of Inflectra be a biosimilar adoption tipping point?

BioPharma Dive spoke to Bert Liang, CEO of Pfenex and chair of the GPhA Biosimilars Council, IP attorney/scientist Stacie Ropka and DRG analysts about how the US biosimilars industry is evolving.

By Nicole Gray • June 9, 2016

Study: Blood-based 'liquid biopsy' cancer testing works

A study that included genetic information from 15,000 patients across 50 tumor types confirmed the accuracy of the tests for diagnostic and tumor-tracking purposes. 

By Nicole Gray • June 8, 2016

Vermont becomes first state with drug pricing justification law

Gov. Peter Shumlin has implemented a law requiring state officials to identify drugs that rose by 50% or more in the last five years. 

By Nicole Gray • June 8, 2016

Genentech/OSI fined $67 million for skewing cancer-drug survival data

According to the Department of Justice (DOJ),  between 2006 and 2011, the two companies misled physicians who treated patients with non-small cell lung cancer (NSCLC) with Tarceva (erlotinib). 

By Nicole Gray • June 8, 2016

Senators request pricing info from opioid-overdose drugmakers

Senators Susan Collins (R-ME) and Claire McCaskill (D-MO) have sent letters to five companies regarding naloxone price hikes. 

By Nicole Gray • June 8, 2016

Study: Cancer drugs most expensive in US, least accessible in China, India

In a study that evaluated cost of cancer drugs as a percentage of per capita GDP, Australia had the most affordable drugs. 

By Nicole Gray • June 6, 2016

AstraZeneca continues to shed rights to gout drug

Germany-based Grünenthal will pay up to $230 million for European and Latin American rights to Zurampic, a month after AstraZeneca sold U.S. rights to Ironwood. 

By Nicole Gray • June 3, 2016

Novartis cancer drug wins expanded indication in Europe

Although Afinitor brought in $1.6 billion last year, sales have dipped as the drug faces stiffer competition.

By Nicole Gray • June 2, 2016

Global cancer drug spending rises, set to surpass $150 billion by 2020

A wave of new drugs entering the market over the past five years has helped drive spending higher, according to a new report from IMS Health.

By Ned Pagliarulo • June 2, 2016

Kite Pharma rides CAR-T momentum into ASCO

BioPharma Dive spoke to the immuno-oncology biotech to find out how its lead cell therapy is progressing as it aims for a 2017 launch.

By Nicole Gray • June 2, 2016

AstraZeneca discontinues 'Take it From a Fish' ad campaign

The campaign had won a prize at the Lions Health festival last year and featured two dead fish joking about triglycerides. 

By Nicole Gray • June 1, 2016

Next-generation eczema drugs on pace for 2017 launch

Anacor Pharma has already submitted its drug, crisaborole, to the FDA for approval, while Regeneron and Sanofi aim to file later this year for their drug dupilumab. 

By Nicole Gray • May 31, 2016